Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 43063-474

5 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 43063-474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063474 Label (43063474)

43063474 Label (43063474)
Label for Atorvastatin Calcium USP 10 mg film-coated tablets, packaged in a quantity of 30 tablets. The label displays the product NDC 43063-474-30 and is issued by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. It includes a warning to keep out of reach of children and space for dosage instructions, along with lot number C20A23 and expiration date 03/2021.*
FDA Label Image

Figure-01 (Figure 01)

Figure-01 (Figure 01)
A line graph comparing the cumulative incidence (%) over time (years) between Atorvastatin and placebo groups. The graph shows two lines: a solid line representing Atorvastatin and a dashed line representing placebo, with the cumulative incidence increasing over approximately 3.5 years. Hazard ratio (HR) and p-value are noted on the graph.*
FDA Label Image

Figure-02 (Figure 02)

Figure-02 (Figure 02)
A Kaplan-Meier curve chart showing cumulative hazard percentage over time (years) for two groups: Placebo and Atorvastatin. The chart covers up to 5 years of follow-up for the time to first primary endpoint, with the Atorvastatin group demonstrating a lower cumulative hazard compared to the Placebo group.*
FDA Label Image

Figure-03 (Figure 03)

Figure-03 (Figure 03)
A line graph showing the percentage of subjects experiencing a major cardiovascular event over time, comparing Atorvastatin 10 mg (dashed line) and Atorvastatin 80 mg (solid line) over a period of 5 years. The x-axis represents time to first major cardiovascular endpoint in years, and the y-axis represents the percentage of subjects experiencing the event. A hazard ratio (HR) of 0.78 with a 95% confidence interval (0.69-0.89) and a p-value of 0.0002 are noted on the graph.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of atorvastatin calcium showing the molecular components, including the calcium ion and associated ligands. The structure represents the active ingredient in the atorvastatin calcium tablet form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.